GALWAY, Ireland -- (BUSINESS WIRE) -- Neuravi, a developer of innovative stroke therapy, announced today that it will introduce the Neuravi Thromboembolic Initiative (NTI) during a series of workshops on “The Science of Clot” at the upcoming European Society of Minimally Invasive Neurological Therapy (ESMINT) conference in Nice. The NTI brings together Neuravi engineers with clinicians and researchers from leading international institutions in an effort to deepen the understanding of the mechanical properties of clot and occlusion dynamics, with the goal of improving the physician’s ability to restore flow in acute ischemic stroke.
The ESMINT conference gathers leaders in minimally invasive neurological therapy from across Europe. "One of the goals of ESMINT is to advance the practice of neuro-intervention through the support of research, education and training," observed Prof. Laurent Pierot, President ESMINT Congress. "Currently, there is a growing interest in identifying different clots and in understanding how different clot characteristics may impact treatment in acute ischemic stroke. The NTI workshops will help in these efforts.”
The NTI workshops will feature a presentation by Dr. Anastasios Mpotsaris, Uniklinik Köln, as well as interactive hands-on sessions with engineers exploring clot characterization, the dynamics of occlusion formation and clot-device interactions and any potential implications for revascularization. Physicians may sign up to attend the sessions being held September 4-6 by registering via email at firstname.lastname@example.org.
"The NTI represents Neuravi’s commitment to advance the treatment of stroke by investing and collaborating in research to unravel the science of stroke occlusion,” stated Eamon Brady, CEO of Neuravi. “We are excited to have this opportunity to both share and learn with the neurointerventional community during these interactive workshops.”
Based in Galway, Ireland, Neuravi is led by a team experienced in endovascular device development and global commercialization. The company’s initial technology platform, the EmboTrap® Revascularization Device, addresses acute ischemic stroke. The EmboTrap received CE Mark in 2013 and is not yet available for use in the United States. In collaboration with international researchers and clinicians, the company seeks to develop new understanding that will drive innovative solutions to treat this challenging and devastating disease.
The Society (European Society of Minimally Invasive Neurological Therapy) has been established in order to promote the benefits of minimally invasive neurological therapies in Europe through education, training and support for high quality scientific research. ESMINT encourages and supports medical practitioners and scientists working to develop and improve minimally invasive methods for the treatment of neurological diseases. These methods will naturally evolve and currently involve the use of image guidance and medical devices such as endovascular catheters to perform treatments with minimum associated trauma.